cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1605Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMВозможности применения комбинированной терапии верапамилом СР и трандолаприлом у больных артериальной гипертонией в группах высокого рискаCombination of verapamil and trandolapril: therapeutic potential for high-risk patients with arterial hypertensionЧихладзеН. М.ChikhladzeN. M.novella.cardio@mail.ruЧазоваИ. Е.ChazovaI. E.novella.cardio@mail.ruИнститут клинической кардиологии им. А.Л. Мясникова ФГУ РК НПК Росмедтехнологии, МоскваA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies, Moscow2007010119706899105Copyright © Чихладзе Н.М., Чазова И.Е., 19701970Чихладзе Н.М., Чазова И.Е.Chikhladze N.M., Chazova I.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1605

Статья посвящена возможностям применения комбинированной терапии верапамилом СР и трандолаприлом у больных артериальной гипертонией (АГ) в группах высокого риска. Проанализированы результаты ряда международных клинических исследований, которые подтверждают эффективность комбинации верапамила СР и трандолаприла (препарат Тарка) при сочетании АГ с ишемической болезнью сердца, сахарным диабетом, при хронических диабетических и недиабетических заболеваниях почек.

The review is devoted to the perspectives of combined therapy with verapamil SR and trandolapril in high-risk patients with arterial hypertension (AH). The results of international clinical trials confirm effectiveness of verapamil SR and trandolapril (Tarka medication) in AH combined with coronary heart disease, diabetes mellitus, chronic diabetic and non-diabetic kidney diseases.

артериальная гипертонияверапамил СРтрандолаприлТаркаорганопротекцияarterial hypertensionverapamil SRtrandolaprilTarkaorgano-protectionReferencesZannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. AJH 1996; 9: 633-43.Zannad F, Matzinger A, Larche J. Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. AJH 1996; 9: 633-43.Messerli F, Frishman WH, Elliot WJ for the Trandolapril Study Group. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens 1998; 11: 633-43.Messerli F, Frishman WH, Elliot WJ for the Trandolapril Study Group. Effects of verapamil and trandolapril in the treatment of hypertension. Am J Hypertens 1998; 11: 633-43.Сonzalez RF, de la Figuera M, Rodriguez GAS. Duration of Trandolapril antihypertensive effects after 24 and 48 hours from the last dose THOR study. Clin Drug Invest 1999; 17 (1): 43-50.Сonzalez RF, de la Figuera M, Rodriguez GAS. Duration of Trandolapril antihypertensive effects after 24 and 48 hours from the last dose THOR study. Clin Drug Invest 1999; 17 (1): 43-50.Viskoper Rg, Compagnone D, Dies R, Zilles P. Verapamil and trandolapril alone and in fixed combination in moderate essential hypertension: a multicenter, double-masked study. Current Ther Res 1997; 58 (6): 331-42.Viskoper Rg, Compagnone D, Dies R, Zilles P. Verapamil and trandolapril alone and in fixed combination in moderate essential hypertension: a multicenter, double-masked study. Current Ther Res 1997; 58 (6): 331-42.Viskoper Rg, Compagnone D, Dies R, Zilles P. Verapamil and trandolapril alone and in fixed combination on 24-hour ambulatory blood pressure profiles of patients with moderate essential hypertension. Current Ther Res 1997; 58 (6): 343-51.Viskoper Rg, Compagnone D, Dies R, Zilles P. Verapamil and trandolapril alone and in fixed combination on 24-hour ambulatory blood pressure profiles of patients with moderate essential hypertension. Current Ther Res 1997; 58 (6): 343-51.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16.Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-16.Hennekens CH, Albert CM, Godfried SL, et al. Adjuncitve drug therapy for acute myocardial infaction – evidence from clinical trials. N Eng J Med 1996; 335: 1660-7.Hennekens CH, Albert CM, Godfried SL, et al. Adjuncitve drug therapy for acute myocardial infaction – evidence from clinical trials. N Eng J Med 1996; 335: 1660-7.Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patient treated with verapamil and trandolapril versus trandolapril alone. Am L Cardiol 1997; 79: 738-41.Hansen JF, Hagerup L, Sigurd B, et al. Cardiac event rates after acute myocardial infarction in patient treated with verapamil and trandolapril versus trandolapril alone. Am L Cardiol 1997; 79: 738-41.Lefrandt JD, Heitmann J, Sevre K, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist on autonomic function in hypertension: the VAMPHYRE Study. AJH 2001; 14: 1083-9.Lefrandt JD, Heitmann J, Sevre K, et al. The effects of dihydropyridine and phenylalkylamine calcium antagonist on autonomic function in hypertension: the VAMPHYRE Study. AJH 2001; 14: 1083-9.Marcus R, Krause L, Weder AB, et al. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation 1994; 90: 928-36.Marcus R, Krause L, Weder AB, et al. Sex-specific determinants of increased left ventricular mass in the Tecumseh Blood Pressure Study. Circulation 1994; 90: 928-36.Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertents 1997; 11 (Suppl 1): S19-27.Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertents 1997; 11 (Suppl 1): S19-27.Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death: Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992; 85: 177-91.Schwartz PJ, La Rovere MT, Vanoli E. Autonomic nervous system and sudden cardiac death: Experimental basis and clinical observations for post-myocardial infarction risk stratification. Circulation 1992; 85: 177-91.Torp-Pedersen C and Kober L for the TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 1999; 354: 9-12.Torp-Pedersen C and Kober L for the TRACE Study Group. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 1999; 354: 9-12.Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular disfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.Kober L, Torp-Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular disfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-6.Fernandez R, Puig JG, Rodriguez-Perez JC, et al. Effects of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomized, double-blind study. J Human Hypertens 2001; 15: 849-56.Fernandez R, Puig JG, Rodriguez-Perez JC, et al. Effects of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomized, double-blind study. J Human Hypertens 2001; 15: 849-56.Bakris G, Molith M, Hewkin N, et al. Differences in glucouse tolersnce between fixed dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-7.Bakris G, Molith M, Hewkin N, et al. Differences in glucouse tolersnce between fixed dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006; 29: 2592-7.Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004; 27: 1330-4.Eurich DT, Majumdar SR, Tsuyuki RT, Johnson JA. Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes. Diabetes Care 2004; 27: 1330-4.Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner & Rector’s The kidney. 7th ed. Vol. 2. Philadelphia: Saunders 2004: 1777-818.Parving HH, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner & Rector’s The kidney. 7th ed. Vol. 2. Philadelphia: Saunders 2004: 1777-818.Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32.Adler AI, Stevens RJ, Manley SE, et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-32.Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60.Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356-60.Nelson RG, Knowler WC, Prettitt DJ, et al. Assessing risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 1991; 151: 1761-5.Nelson RG, Knowler WC, Prettitt DJ, et al. Assessing risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 1991; 151: 1761-5.Ruggenenti P, Fassi A. Ilieva AP, et al. Preventing Microalbuminuria in type 2 diabetes. N Eng J Med 2004; 351 (19): 1941-51.Ruggenenti P, Fassi A. Ilieva AP, et al. Preventing Microalbuminuria in type 2 diabetes. N Eng J Med 2004; 351 (19): 1941-51.Bakris GL. Weir MR, DeQuattro V, Mc Mahon FY. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54 (4): 1283-9.Bakris GL. Weir MR, DeQuattro V, Mc Mahon FY. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int 1998; 54 (4): 1283-9.The PROCOPA study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomised double-blind trial. J Hypertens 2002; 20: 729-37.The PROCOPA study Group. Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomised double-blind trial. J Hypertens 2002; 20: 729-37.

The authors declare that there are no conflicts of interest present.